We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Compelling Reasons to Hold on to Ensign Group (ENSG) Stock
Read MoreHide Full Article
The Ensign Group, Inc. (ENSG - Free Report) is benefiting on the back of solid segmental contributions, acquisitions of healthcare facilities and a robust financial position. A positive business outlook for 2024 reinforces investors’ confidence in the stock.
Zacks Rank & Price Performance
Ensign Group carries a Zacks Rank #3 (Hold), at present.
The stock has gained 31.7% in the past year.
Image Source: Zacks Investment Research
Robust Growth Prospects
The Zacks Consensus Estimate for Ensign Group’s 2024 earnings is pegged at $5.39 per share, indicating an improvement of 13% from the year-earlier reading, while the same for revenues is $4.1 billion, implying an 11% increase from the prior year actual.
The consensus mark for 2025 earnings is pegged at $5.91 per share, suggesting 9.6% growth from the 2024 estimate. The same for revenues is $4.5 billion, which indicates a rise of 9.4% from the 2024 estimate.
Northbound Estimate Revision
The Zacks Consensus Estimate for 2024 earnings has been revised 0.2% upward in the past 30 days.
Impressive Surprise History
ENSG’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 1.25%.
Solid Return on Equity
Ensign Group’s efficiency in utilizing shareholders’ funds can be substantiated by its return on equity of 19.1% against the industry’s negative return of 13.8%.
A Favorable 2024 Outlook
ENSG projects revenues within the range of $4.13-$4.17 billion in 2024, the midpoint of which indicates 11.3% growth from the 2023 reported figure.
Adjusted earnings per share are anticipated to lie between $5.29 and $5.47. The midpoint of the outlook suggests 13% growth from the 2023 reported figure.
Key Business Tailwinds
Over the past decade, Ensign Group has witnessed a CAGR of 16.3% in its top line. In the first quarter, the metric improved 13.9% year over year, driven by increased service revenues.
Ensign Group's Skilled Services segment offers skilled nursing, senior living services, physical, occupational, and speech therapies, along with other rehabilitative and healthcare services. The aging U.S. population is expected to sustain the high demand for senior living services, while the need for effective rehabilitation services, which help individuals resume daily activities, provides a strong growth opportunity for ENSG.
In addition to the contributions from the Skilled Services unit, the Standard Bearer segment represents the growing real estate portfolio of Ensign Group. This unit engages in triple-net lease arrangements with healthcare operators for post-acute care properties acquired by ENSG.
Ensign Group actively pursues an inorganic growth strategy, primarily through facility acquisitions. Each acquisition enhances the company’s capabilities and expands its nationwide presence. These acquisitions also enable ENSG to collaborate closely with skilled caregivers at each facility, gaining valuable insights into various U.S. communities.
These expansion efforts have significantly broadened Ensign Group's healthcare portfolio, which presently includes 310 healthcare operations across 13 states, with 29 senior living operations. It also owns 119 real estate assets.
Maintaining a solid financial position is crucial for supporting ongoing growth investments. Ensign Group has growing cash reserves and sound cash-generating abilities. This robust financial foundation allows the company to invest in its business strategically, as well as engage in share buybacks and dividend payments. ENSG has consistently paid dividends for more than two decades. Its dividend yield of 0.21% compares favorably with the industry’s figure of 0.17%.
Ensign Group also benefits from an improving leverage ratio. Its total debt-to-total capital of 8.6% at the end of the first quarter is significantly lower than the industry average of 82.3%.
Tenet Healthcare’s earnings surpassed estimates in each of the last four quarters, the average surprise being 56.50%. The Zacks Consensus Estimate for THC’s 2024 earnings indicates a 20.6% rise from the prior-year tally. The consensus mark for THC’s 2024 earnings has moved 36.9% north in the past 30 days.
The bottom line of Alcon outpaced estimates in three of the trailing four quarters and missed the mark once, the average surprise being 5.27%. The Zacks Consensus Estimate for ALC’s 2024 earnings indicates an 11.3% rise, while the consensus mark for revenues suggests an improvement of 6.2% from the respective prior-year figures. The consensus mark for ALC’s 2024 earnings has moved 0.3% north in the past 60 days.
LeMaitre Vascular’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 10.12%. The Zacks Consensus Estimate for LMAT’s 2024 earnings indicates a 28.2% rise, while the same for revenues suggests an improvement of 11.3% from the respective prior-year tallies. The consensus mark for LMAT’s 2024 earnings has moved up 5.5% in the past 30 days.
Shares of Tenet Healthcare, Alcon and LeMaitre Vascular have gained 91.4%, 13.2% and 27.8%, respectively, in the past year.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Compelling Reasons to Hold on to Ensign Group (ENSG) Stock
The Ensign Group, Inc. (ENSG - Free Report) is benefiting on the back of solid segmental contributions, acquisitions of healthcare facilities and a robust financial position. A positive business outlook for 2024 reinforces investors’ confidence in the stock.
Zacks Rank & Price Performance
Ensign Group carries a Zacks Rank #3 (Hold), at present.
The stock has gained 31.7% in the past year.
Image Source: Zacks Investment Research
Robust Growth Prospects
The Zacks Consensus Estimate for Ensign Group’s 2024 earnings is pegged at $5.39 per share, indicating an improvement of 13% from the year-earlier reading, while the same for revenues is $4.1 billion, implying an 11% increase from the prior year actual.
The consensus mark for 2025 earnings is pegged at $5.91 per share, suggesting 9.6% growth from the 2024 estimate. The same for revenues is $4.5 billion, which indicates a rise of 9.4% from the 2024 estimate.
Northbound Estimate Revision
The Zacks Consensus Estimate for 2024 earnings has been revised 0.2% upward in the past 30 days.
Impressive Surprise History
ENSG’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 1.25%.
Solid Return on Equity
Ensign Group’s efficiency in utilizing shareholders’ funds can be substantiated by its return on equity of 19.1% against the industry’s negative return of 13.8%.
A Favorable 2024 Outlook
ENSG projects revenues within the range of $4.13-$4.17 billion in 2024, the midpoint of which indicates 11.3% growth from the 2023 reported figure.
Adjusted earnings per share are anticipated to lie between $5.29 and $5.47. The midpoint of the outlook suggests 13% growth from the 2023 reported figure.
Key Business Tailwinds
Over the past decade, Ensign Group has witnessed a CAGR of 16.3% in its top line. In the first quarter, the metric improved 13.9% year over year, driven by increased service revenues.
Ensign Group's Skilled Services segment offers skilled nursing, senior living services, physical, occupational, and speech therapies, along with other rehabilitative and healthcare services. The aging U.S. population is expected to sustain the high demand for senior living services, while the need for effective rehabilitation services, which help individuals resume daily activities, provides a strong growth opportunity for ENSG.
In addition to the contributions from the Skilled Services unit, the Standard Bearer segment represents the growing real estate portfolio of Ensign Group. This unit engages in triple-net lease arrangements with healthcare operators for post-acute care properties acquired by ENSG.
Ensign Group actively pursues an inorganic growth strategy, primarily through facility acquisitions. Each acquisition enhances the company’s capabilities and expands its nationwide presence. These acquisitions also enable ENSG to collaborate closely with skilled caregivers at each facility, gaining valuable insights into various U.S. communities.
These expansion efforts have significantly broadened Ensign Group's healthcare portfolio, which presently includes 310 healthcare operations across 13 states, with 29 senior living operations. It also owns 119 real estate assets.
Maintaining a solid financial position is crucial for supporting ongoing growth investments. Ensign Group has growing cash reserves and sound cash-generating abilities. This robust financial foundation allows the company to invest in its business strategically, as well as engage in share buybacks and dividend payments. ENSG has consistently paid dividends for more than two decades. Its dividend yield of 0.21% compares favorably with the industry’s figure of 0.17%.
Ensign Group also benefits from an improving leverage ratio. Its total debt-to-total capital of 8.6% at the end of the first quarter is significantly lower than the industry average of 82.3%.
Stocks to Consider
Some better-ranked stocks in the Medical space are Tenet Healthcare Corporation (THC - Free Report) , Alcon Inc. (ALC - Free Report) and LeMaitre Vascular, Inc. (LMAT - Free Report) . While Tenet Healthcare sports a Zacks Rank #1 (Strong Buy), Alcon and LeMaitre Vascular carry a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Tenet Healthcare’s earnings surpassed estimates in each of the last four quarters, the average surprise being 56.50%. The Zacks Consensus Estimate for THC’s 2024 earnings indicates a 20.6% rise from the prior-year tally. The consensus mark for THC’s 2024 earnings has moved 36.9% north in the past 30 days.
The bottom line of Alcon outpaced estimates in three of the trailing four quarters and missed the mark once, the average surprise being 5.27%. The Zacks Consensus Estimate for ALC’s 2024 earnings indicates an 11.3% rise, while the consensus mark for revenues suggests an improvement of 6.2% from the respective prior-year figures. The consensus mark for ALC’s 2024 earnings has moved 0.3% north in the past 60 days.
LeMaitre Vascular’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 10.12%. The Zacks Consensus Estimate for LMAT’s 2024 earnings indicates a 28.2% rise, while the same for revenues suggests an improvement of 11.3% from the respective prior-year tallies. The consensus mark for LMAT’s 2024 earnings has moved up 5.5% in the past 30 days.
Shares of Tenet Healthcare, Alcon and LeMaitre Vascular have gained 91.4%, 13.2% and 27.8%, respectively, in the past year.